Investor Zone
U-NEURON Unveils i-ExoCraft® Intelligent Integrated Platform, Ushering Exosomes into a New Era of Design and Foundry Services
Economic Daily News / Reporter Po-Hong Hsieh
Chlitina Holding Partners with U-NEURON to Launch Deer Amniotic Exosome Skincare Series, Surpassing RMB 10 Million in Single-Day Global Debut Sales
Chlitina Holding (4137) has joined forces with U-NEURON (6973) to develop deer amniotic fluid stem cell exosome beauty and skincare products. The companies recently held the grand "CHLITINA Golden Bandage Global Debut Launch Event" in Wuhan, Mainland China, generating single-day launch sales exceeding RMB 10 million! This milestone is expected to further boost revenue for both companies this year.
U-NEURON Launches Exosome R&D Pilot Manufacturing Center to Capture Multi-Billion Exosome Market Opportunities
Economic Daily News / Reporter Po-Hong Hsieh
U-NEURON’s Amniotic Fluid Stem Cell New Drug Secures Dual ExpeditedRegulatory Guidance for Regenerative Medicine
U-NEURON (6973-TW) announced today (22nd) that its proprietary new drug candidate UA002, designed for the treatment of erectile dysfunction, has been approved by Taiwan TFDA under the "Project-Based Advisory and Guidance Cases" scheme. Concurrently, UA002 secured the "Flagship Project" (Index Case) qualification from the Center for Drug Evaluation (CDE). Under this dedicated advisory framework, the company expects to accelerate development and regulatory review while mitigating R&D risks, marking dual expeditedregulatory support in the regenerative medicine arena.